ONCOETHIX GmbH

Patent Applications and Registrations

Patent applications and USPTO patent grants for ONCOETHIX GmbH.The latest application filed is for "pharmaceutical doses for a bromodomain and extraterminal protein (bet) inhibitor".

Company Profile

2.10.21

ONCOETHIX GmbH - Lucerne N/A CH
ONCOETHIX GmbH - Lausanne N/A CH
ONCOETHIX GmbH - Luzern CH
ONCOETHIX GmbH - Laysanne CH

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods of treating lymphoma using thienotriazolodiazepine compounds Grant 9,968,620 - Bertoni May 15, 2	2018-05-15
Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds Grant 9,968,619 - Noel , et al. May 15, 2	2018-05-15
Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds Grant 9,956,228 - Noel , et al. May 1, 2	2018-05-01
Pharmaceutical Doses For A Bromodomain And Extraterminal Protein (bet) Inhibitor App 20180098997 - Cvitkovic; Esteban ; et al.	2018-04-12
Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds Grant 9,901,583 - Riveiro , et al. February 27, 2	2018-02-27
Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds Grant 9,820,992 - Riveiro , et al. November 21, 2	2017-11-21
Methods Of Treating Acute Myeloid Leukemia Or Acute Lymphoid Leukemia Using Pharmaceutical Compositions Containing Thienotriazolodiazepine Compounds App 20170281642 - Dombret; Herve	2017-10-05
Methods Of Treating Lymphoma Using Thienotriazolodiazepine Compounds App 20170273988 - Bertoni; Francesco	2017-09-28
Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds Grant 9,757,385 - Riveiro , et al. September 12, 2	2017-09-12
Method Of Treating Leukemia Using Pharmaceutical Formulation Containing Thienotriazolodiazepine Compounds App 20170157141 - RIVEIRO; Maria E. ; et al.	2017-06-08
Method Of Treating Non-small Cell Lung Cancer And/or Small Cell Lung Cancer Using Thienotriazolodiazepine Compounds App 20170151255 - Riveiro; Maria Eugenia ; et al.	2017-06-01
Method Of Treating Resistant Non-hodgkin Lymphoma, Medulloblastoma, And/or Alk+non-small Cell Lung Cancer Using Thienotriazolodiazepine Compounds App 20170095484 - Noel; Kay	2017-04-06
Method Of Treating Triple-negative Breast Cancer Using Thienotriazolodiazepine Compounds App 20170065607 - NOEL; Kay ; et al.	2017-03-09
Method Of Treating Acute Myeloid Leukemia And/or Acute Lymphoblastic Leukemia Using Thienotriazolodiazepine Compounds App 20170049784 - Noel; Kay ; et al.	2017-02-23
Method Of Treating Non-small-cell Lung Cancer Using Pharmaceutical Formulation Containing Thienotriazolodiazepine Compounds App 20160375032 - Riveiro; Maria E. ; et al.	2016-12-29
Method Of Treating Diffuse Large B-cell Lymphoma (dlbcl) Using A Bet-bromodomain Inhibitor App 20160158246 - Bertoni; Francesco ; et al.	2016-06-09
Pharmaceutical Formulation Containing Thienotriazolodiazepine Compounds App 20160158245 - DOMBRET; Herve	2016-06-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.